Global Blood Coagulants Market

Blood Coagulants Comprehensive Study by Type (Aprotinin, Tranexamic Acid (TXA), Epsilon-Aminocaproic acid, Aminomethylbenzoic acid, Other), Application (Hemophilia, Surgery (Post-Operative Care), Menstruation (Bleeding Disorders), Others), Coagulation Factor (Recombinant Coagulation Factor, Plasma-Derived Coagulation Factor), End-Users (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, General Pharmacies, Others), Clot Pathway Factors (X Factor, V Factor, II Factor, I Factor, XIII Factor), Coagulation Tests (Complete blood count (CBC), Factor V assay, Fibrinogen level, Prothrombin time (PT or PT-INR), Others) Players and Region - Global Market Outlook to 2030

Blood Coagulants Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Blood Coagulants
Blood Coagulants helps in converting blood into a gel or a clot formation. The utmost importance of these coagulants is driven by factors namely increased bleeding disorders, in research activities, and an increase in the healthcare project grants provided by public and private organizations, among others. In addition to that the cumulating awareness that is created by various organizations, as well as government so that it can help to increase the growth of the market. According to the World Federation of Hemophilia (WFH), they launched a Development Grant Program (DGP) in 2018 so that they can encourage innovative ideas and projects in order to support the inherited bleeding disorders community globally. Hence enhancing the market for blood coagulants, due to its importance for survivors of humankind.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The global blood coagulant market is dominated by many market players. The key players in the market are very much concentrated with new product launches and strategic collaborations so that they can strengthen their market position. For instance, in May 2016, CSL Behring announced the United States FDA approval of AFSTYLA, a recombinant factor VIII single-chain therapy for Hemophilia A. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Blood Coagulants market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Sanofi (France), Abbott Laboratories (United States), Bayer AG (Germany), Pfizer Inc. (United States), Novo Nordisk AS (Denmark), Octapharma (Switzerland), SOBI (Sweden), Shire (Republic of Ireland) and CSL Limited (Australia) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are BPL (United Kingdom) and Kedrion (Italy).

Segmentation Overview
AMA Research has segmented the market of Global Blood Coagulants market by Type (Aprotinin, Tranexamic Acid (TXA), Epsilon-Aminocaproic acid, Aminomethylbenzoic acid and Other), Application (Hemophilia, Surgery (Post-Operative Care), Menstruation (Bleeding Disorders) and Others) and Region.



On the basis of geography, the market of Blood Coagulants has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, New Zealand, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Sweden, Finland, Ireland, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Coagulation Factor, the sub-segment i.e. Recombinant Coagulation Factor will boost the Blood Coagulants market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-Users, the sub-segment i.e. Hospitals will boost the Blood Coagulants market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Clot Pathway Factors, the sub-segment i.e. X Factor will boost the Blood Coagulants market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Coagulation Tests, the sub-segment i.e. Complete blood count (CBC) will boost the Blood Coagulants market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rise in Technology at Plasma Collection Centers to Collect Plasma and Record Patient History

Market Growth Drivers:
Increasing Prevalence of Cardiovascular Diseases, Blood-Related Diseases and The Rising number of Accidental Injuries

Challenges:
Stringent Regulatory Policies and Shortage in Plasma Supply

Restraints:
The lack of awareness regarding blood clotting and its importance coupled with the high cost of diagnostic tests in some developing economies. In addition to that, the rising counterfeit drugs are restraining the market. According to the National Hemophilia Foundation, it is seen that 75% of hemophilic people worldwide receive inadequate treatment or have no access to this treatment, hence making a challenge in this market.

Opportunities:
Increasing Demand for Life Saving Drugs Due To Increasing Population, Rising Geriatric Population Worldwide and Growing Healthcare Infrastructure in Developing Countries

Market Leaders and their expansionary development strategies
In December 2023, Stago, a leading French diagnostics company, acquired Hemosphere, a U.S. provider of point-of-care hemostasis testing solutions. This move strengthens Stago's position in the global hemostasis testing market and expands its product offerings.
On October 26, 2023, Roche and Sangamo Therapeutics entered into a strategic partnership to develop gene editing therapies for various diseases, including hemophilia B. This collaboration combines Roche's commercialization expertise with Sangamo's innovative gene editing technology.
According to Food and Drugs, The Center for Biologics Evaluation and Research (CBER) regulates the collection of blood and blood components used for transfusion or for the manufacture of pharmaceuticals derived from blood and blood components, such as clotting factors, and establishes standards for the products themselves. CBER also regulates related products such as cell separation devices, blood collection containers and HIV screening tests that are used to prepare blood products or to ensure the safety of the blood supply. CBER develops and enforces quality standards, inspects blood establishments and monitors reports of errors, accidents and adverse clinical events.

Key Target Audience
Potential Investors, Government Bodies and Associations, Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Aprotinin
  • Tranexamic Acid (TXA)
  • Epsilon-Aminocaproic acid
  • Aminomethylbenzoic acid
  • Other
By Application
  • Hemophilia
  • Surgery (Post-Operative Care)
  • Menstruation (Bleeding Disorders)
  • Others
By Coagulation Factor
  • Recombinant Coagulation Factor
  • Plasma-Derived Coagulation Factor

By End-Users
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • General Pharmacies
  • Others

By Clot Pathway Factors
  • X Factor
  • V Factor
  • II Factor
  • I Factor
  • XIII Factor

By Coagulation Tests
  • Complete blood count (CBC)
  • Factor V assay
  • Fibrinogen level
  • Prothrombin time (PT or PT-INR)
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • New Zealand
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Sweden
    • Finland
    • Ireland
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Cardiovascular Diseases, Blood-Related Diseases
      • 3.2.2. The Rising number of Accidental Injuries
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Policies
      • 3.3.2. Shortage in Plasma Supply
    • 3.4. Market Trends
      • 3.4.1. Rise in Technology at Plasma Collection Centers to Collect Plasma and Record Patient History
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Blood Coagulants, by Type, Application, Coagulation Factor, End-Users, Clot Pathway Factors, Coagulation Tests and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Blood Coagulants (Value)
      • 5.2.1. Global Blood Coagulants by: Type (Value)
        • 5.2.1.1. Aprotinin
        • 5.2.1.2. Tranexamic Acid (TXA)
        • 5.2.1.3. Epsilon-Aminocaproic acid
        • 5.2.1.4. Aminomethylbenzoic acid
        • 5.2.1.5. Other
      • 5.2.2. Global Blood Coagulants by: Application (Value)
        • 5.2.2.1. Hemophilia
        • 5.2.2.2. Surgery (Post-Operative Care)
        • 5.2.2.3. Menstruation (Bleeding Disorders)
        • 5.2.2.4. Others
      • 5.2.3. Global Blood Coagulants by: Coagulation Factor (Value)
        • 5.2.3.1. Recombinant Coagulation Factor
        • 5.2.3.2. Plasma-Derived Coagulation Factor
      • 5.2.4. Global Blood Coagulants by: End-Users (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Specialty Clinics
        • 5.2.4.3. Ambulatory Surgical Centers
        • 5.2.4.4. General Pharmacies
        • 5.2.4.5. Others
      • 5.2.5. Global Blood Coagulants by: Clot Pathway Factors (Value)
        • 5.2.5.1. X Factor
        • 5.2.5.2. V Factor
        • 5.2.5.3. II Factor
        • 5.2.5.4. I Factor
        • 5.2.5.5. XIII Factor
      • 5.2.6. Global Blood Coagulants by: Coagulation Tests (Value)
        • 5.2.6.1. Complete blood count (CBC)
        • 5.2.6.2. Factor V assay
        • 5.2.6.3. Fibrinogen level
        • 5.2.6.4. Prothrombin time (PT or PT-INR)
        • 5.2.6.5. Others
      • 5.2.7. Global Blood Coagulants Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. New Zealand
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Sweden
          • 5.2.7.3.6. Finland
          • 5.2.7.3.7. Ireland
          • 5.2.7.3.8. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
    • 5.3. Global Blood Coagulants (Price)
      • 5.3.1. Global Blood Coagulants by: Type (Price)
  • 6. Blood Coagulants: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novo Nordisk AS (Denmark)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Octapharma (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. SOBI (Sweden)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Shire (Republic of Ireland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. CSL Limited (Australia)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Blood Coagulants Sale, by Type, Application, Coagulation Factor, End-Users, Clot Pathway Factors, Coagulation Tests and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Blood Coagulants (Value)
      • 7.2.1. Global Blood Coagulants by: Type (Value)
        • 7.2.1.1. Aprotinin
        • 7.2.1.2. Tranexamic Acid (TXA)
        • 7.2.1.3. Epsilon-Aminocaproic acid
        • 7.2.1.4. Aminomethylbenzoic acid
        • 7.2.1.5. Other
      • 7.2.2. Global Blood Coagulants by: Application (Value)
        • 7.2.2.1. Hemophilia
        • 7.2.2.2. Surgery (Post-Operative Care)
        • 7.2.2.3. Menstruation (Bleeding Disorders)
        • 7.2.2.4. Others
      • 7.2.3. Global Blood Coagulants by: Coagulation Factor (Value)
        • 7.2.3.1. Recombinant Coagulation Factor
        • 7.2.3.2. Plasma-Derived Coagulation Factor
      • 7.2.4. Global Blood Coagulants by: End-Users (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Specialty Clinics
        • 7.2.4.3. Ambulatory Surgical Centers
        • 7.2.4.4. General Pharmacies
        • 7.2.4.5. Others
      • 7.2.5. Global Blood Coagulants by: Clot Pathway Factors (Value)
        • 7.2.5.1. X Factor
        • 7.2.5.2. V Factor
        • 7.2.5.3. II Factor
        • 7.2.5.4. I Factor
        • 7.2.5.5. XIII Factor
      • 7.2.6. Global Blood Coagulants by: Coagulation Tests (Value)
        • 7.2.6.1. Complete blood count (CBC)
        • 7.2.6.2. Factor V assay
        • 7.2.6.3. Fibrinogen level
        • 7.2.6.4. Prothrombin time (PT or PT-INR)
        • 7.2.6.5. Others
      • 7.2.7. Global Blood Coagulants Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. New Zealand
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Sweden
          • 7.2.7.3.6. Finland
          • 7.2.7.3.7. Ireland
          • 7.2.7.3.8. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
    • 7.3. Global Blood Coagulants (Price)
      • 7.3.1. Global Blood Coagulants by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Blood Coagulants: by Type(USD Million)
  • Table 2. Blood Coagulants Aprotinin , by Region USD Million (2018-2023)
  • Table 3. Blood Coagulants Tranexamic Acid (TXA) , by Region USD Million (2018-2023)
  • Table 4. Blood Coagulants Epsilon-Aminocaproic acid , by Region USD Million (2018-2023)
  • Table 5. Blood Coagulants Aminomethylbenzoic acid , by Region USD Million (2018-2023)
  • Table 6. Blood Coagulants Other , by Region USD Million (2018-2023)
  • Table 7. Blood Coagulants: by Application(USD Million)
  • Table 8. Blood Coagulants Hemophilia , by Region USD Million (2018-2023)
  • Table 9. Blood Coagulants Surgery (Post-Operative Care) , by Region USD Million (2018-2023)
  • Table 10. Blood Coagulants Menstruation (Bleeding Disorders) , by Region USD Million (2018-2023)
  • Table 11. Blood Coagulants Others , by Region USD Million (2018-2023)
  • Table 12. Blood Coagulants: by Coagulation Factor(USD Million)
  • Table 13. Blood Coagulants Recombinant Coagulation Factor , by Region USD Million (2018-2023)
  • Table 14. Blood Coagulants Plasma-Derived Coagulation Factor , by Region USD Million (2018-2023)
  • Table 15. Blood Coagulants: by End-Users(USD Million)
  • Table 16. Blood Coagulants Hospitals , by Region USD Million (2018-2023)
  • Table 17. Blood Coagulants Specialty Clinics , by Region USD Million (2018-2023)
  • Table 18. Blood Coagulants Ambulatory Surgical Centers , by Region USD Million (2018-2023)
  • Table 19. Blood Coagulants General Pharmacies , by Region USD Million (2018-2023)
  • Table 20. Blood Coagulants Others , by Region USD Million (2018-2023)
  • Table 21. Blood Coagulants: by Clot Pathway Factors(USD Million)
  • Table 22. Blood Coagulants X Factor , by Region USD Million (2018-2023)
  • Table 23. Blood Coagulants V Factor , by Region USD Million (2018-2023)
  • Table 24. Blood Coagulants II Factor , by Region USD Million (2018-2023)
  • Table 25. Blood Coagulants I Factor , by Region USD Million (2018-2023)
  • Table 26. Blood Coagulants XIII Factor , by Region USD Million (2018-2023)
  • Table 27. Blood Coagulants: by Coagulation Tests(USD Million)
  • Table 28. Blood Coagulants Complete blood count (CBC) , by Region USD Million (2018-2023)
  • Table 29. Blood Coagulants Factor V assay , by Region USD Million (2018-2023)
  • Table 30. Blood Coagulants Fibrinogen level , by Region USD Million (2018-2023)
  • Table 31. Blood Coagulants Prothrombin time (PT or PT-INR) , by Region USD Million (2018-2023)
  • Table 32. Blood Coagulants Others , by Region USD Million (2018-2023)
  • Table 33. South America Blood Coagulants, by Country USD Million (2018-2023)
  • Table 34. South America Blood Coagulants, by Type USD Million (2018-2023)
  • Table 35. South America Blood Coagulants, by Application USD Million (2018-2023)
  • Table 36. South America Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 37. South America Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 38. South America Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 39. South America Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 40. Brazil Blood Coagulants, by Type USD Million (2018-2023)
  • Table 41. Brazil Blood Coagulants, by Application USD Million (2018-2023)
  • Table 42. Brazil Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 43. Brazil Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 44. Brazil Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 45. Brazil Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 46. Argentina Blood Coagulants, by Type USD Million (2018-2023)
  • Table 47. Argentina Blood Coagulants, by Application USD Million (2018-2023)
  • Table 48. Argentina Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 49. Argentina Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 50. Argentina Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 51. Argentina Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 52. Rest of South America Blood Coagulants, by Type USD Million (2018-2023)
  • Table 53. Rest of South America Blood Coagulants, by Application USD Million (2018-2023)
  • Table 54. Rest of South America Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 55. Rest of South America Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 56. Rest of South America Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 57. Rest of South America Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 58. Asia Pacific Blood Coagulants, by Country USD Million (2018-2023)
  • Table 59. Asia Pacific Blood Coagulants, by Type USD Million (2018-2023)
  • Table 60. Asia Pacific Blood Coagulants, by Application USD Million (2018-2023)
  • Table 61. Asia Pacific Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 62. Asia Pacific Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 63. Asia Pacific Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 64. Asia Pacific Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 65. China Blood Coagulants, by Type USD Million (2018-2023)
  • Table 66. China Blood Coagulants, by Application USD Million (2018-2023)
  • Table 67. China Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 68. China Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 69. China Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 70. China Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 71. Japan Blood Coagulants, by Type USD Million (2018-2023)
  • Table 72. Japan Blood Coagulants, by Application USD Million (2018-2023)
  • Table 73. Japan Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 74. Japan Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 75. Japan Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 76. Japan Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 77. India Blood Coagulants, by Type USD Million (2018-2023)
  • Table 78. India Blood Coagulants, by Application USD Million (2018-2023)
  • Table 79. India Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 80. India Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 81. India Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 82. India Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 83. South Korea Blood Coagulants, by Type USD Million (2018-2023)
  • Table 84. South Korea Blood Coagulants, by Application USD Million (2018-2023)
  • Table 85. South Korea Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 86. South Korea Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 87. South Korea Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 88. South Korea Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 89. New Zealand Blood Coagulants, by Type USD Million (2018-2023)
  • Table 90. New Zealand Blood Coagulants, by Application USD Million (2018-2023)
  • Table 91. New Zealand Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 92. New Zealand Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 93. New Zealand Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 94. New Zealand Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 95. Australia Blood Coagulants, by Type USD Million (2018-2023)
  • Table 96. Australia Blood Coagulants, by Application USD Million (2018-2023)
  • Table 97. Australia Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 98. Australia Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 99. Australia Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 100. Australia Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 101. Rest of Asia-Pacific Blood Coagulants, by Type USD Million (2018-2023)
  • Table 102. Rest of Asia-Pacific Blood Coagulants, by Application USD Million (2018-2023)
  • Table 103. Rest of Asia-Pacific Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 104. Rest of Asia-Pacific Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 105. Rest of Asia-Pacific Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 106. Rest of Asia-Pacific Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 107. Europe Blood Coagulants, by Country USD Million (2018-2023)
  • Table 108. Europe Blood Coagulants, by Type USD Million (2018-2023)
  • Table 109. Europe Blood Coagulants, by Application USD Million (2018-2023)
  • Table 110. Europe Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 111. Europe Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 112. Europe Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 113. Europe Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 114. Germany Blood Coagulants, by Type USD Million (2018-2023)
  • Table 115. Germany Blood Coagulants, by Application USD Million (2018-2023)
  • Table 116. Germany Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 117. Germany Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 118. Germany Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 119. Germany Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 120. France Blood Coagulants, by Type USD Million (2018-2023)
  • Table 121. France Blood Coagulants, by Application USD Million (2018-2023)
  • Table 122. France Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 123. France Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 124. France Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 125. France Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 126. Italy Blood Coagulants, by Type USD Million (2018-2023)
  • Table 127. Italy Blood Coagulants, by Application USD Million (2018-2023)
  • Table 128. Italy Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 129. Italy Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 130. Italy Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 131. Italy Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 132. United Kingdom Blood Coagulants, by Type USD Million (2018-2023)
  • Table 133. United Kingdom Blood Coagulants, by Application USD Million (2018-2023)
  • Table 134. United Kingdom Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 135. United Kingdom Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 136. United Kingdom Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 137. United Kingdom Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 138. Sweden Blood Coagulants, by Type USD Million (2018-2023)
  • Table 139. Sweden Blood Coagulants, by Application USD Million (2018-2023)
  • Table 140. Sweden Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 141. Sweden Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 142. Sweden Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 143. Sweden Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 144. Finland Blood Coagulants, by Type USD Million (2018-2023)
  • Table 145. Finland Blood Coagulants, by Application USD Million (2018-2023)
  • Table 146. Finland Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 147. Finland Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 148. Finland Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 149. Finland Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 150. Ireland Blood Coagulants, by Type USD Million (2018-2023)
  • Table 151. Ireland Blood Coagulants, by Application USD Million (2018-2023)
  • Table 152. Ireland Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 153. Ireland Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 154. Ireland Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 155. Ireland Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 156. Rest of Europe Blood Coagulants, by Type USD Million (2018-2023)
  • Table 157. Rest of Europe Blood Coagulants, by Application USD Million (2018-2023)
  • Table 158. Rest of Europe Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 159. Rest of Europe Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 160. Rest of Europe Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 161. Rest of Europe Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 162. MEA Blood Coagulants, by Country USD Million (2018-2023)
  • Table 163. MEA Blood Coagulants, by Type USD Million (2018-2023)
  • Table 164. MEA Blood Coagulants, by Application USD Million (2018-2023)
  • Table 165. MEA Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 166. MEA Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 167. MEA Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 168. MEA Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 169. Middle East Blood Coagulants, by Type USD Million (2018-2023)
  • Table 170. Middle East Blood Coagulants, by Application USD Million (2018-2023)
  • Table 171. Middle East Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 172. Middle East Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 173. Middle East Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 174. Middle East Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 175. Africa Blood Coagulants, by Type USD Million (2018-2023)
  • Table 176. Africa Blood Coagulants, by Application USD Million (2018-2023)
  • Table 177. Africa Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 178. Africa Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 179. Africa Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 180. Africa Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 181. North America Blood Coagulants, by Country USD Million (2018-2023)
  • Table 182. North America Blood Coagulants, by Type USD Million (2018-2023)
  • Table 183. North America Blood Coagulants, by Application USD Million (2018-2023)
  • Table 184. North America Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 185. North America Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 186. North America Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 187. North America Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 188. United States Blood Coagulants, by Type USD Million (2018-2023)
  • Table 189. United States Blood Coagulants, by Application USD Million (2018-2023)
  • Table 190. United States Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 191. United States Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 192. United States Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 193. United States Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 194. Canada Blood Coagulants, by Type USD Million (2018-2023)
  • Table 195. Canada Blood Coagulants, by Application USD Million (2018-2023)
  • Table 196. Canada Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 197. Canada Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 198. Canada Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 199. Canada Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 200. Mexico Blood Coagulants, by Type USD Million (2018-2023)
  • Table 201. Mexico Blood Coagulants, by Application USD Million (2018-2023)
  • Table 202. Mexico Blood Coagulants, by Coagulation Factor USD Million (2018-2023)
  • Table 203. Mexico Blood Coagulants, by End-Users USD Million (2018-2023)
  • Table 204. Mexico Blood Coagulants, by Clot Pathway Factors USD Million (2018-2023)
  • Table 205. Mexico Blood Coagulants, by Coagulation Tests USD Million (2018-2023)
  • Table 206. Blood Coagulants: by Type(USD/Units)
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Company Basic Information, Sales Area and Its Competitors
  • Table 210. Company Basic Information, Sales Area and Its Competitors
  • Table 211. Company Basic Information, Sales Area and Its Competitors
  • Table 212. Company Basic Information, Sales Area and Its Competitors
  • Table 213. Company Basic Information, Sales Area and Its Competitors
  • Table 214. Company Basic Information, Sales Area and Its Competitors
  • Table 215. Company Basic Information, Sales Area and Its Competitors
  • Table 216. Blood Coagulants: by Type(USD Million)
  • Table 217. Blood Coagulants Aprotinin , by Region USD Million (2025-2030)
  • Table 218. Blood Coagulants Tranexamic Acid (TXA) , by Region USD Million (2025-2030)
  • Table 219. Blood Coagulants Epsilon-Aminocaproic acid , by Region USD Million (2025-2030)
  • Table 220. Blood Coagulants Aminomethylbenzoic acid , by Region USD Million (2025-2030)
  • Table 221. Blood Coagulants Other , by Region USD Million (2025-2030)
  • Table 222. Blood Coagulants: by Application(USD Million)
  • Table 223. Blood Coagulants Hemophilia , by Region USD Million (2025-2030)
  • Table 224. Blood Coagulants Surgery (Post-Operative Care) , by Region USD Million (2025-2030)
  • Table 225. Blood Coagulants Menstruation (Bleeding Disorders) , by Region USD Million (2025-2030)
  • Table 226. Blood Coagulants Others , by Region USD Million (2025-2030)
  • Table 227. Blood Coagulants: by Coagulation Factor(USD Million)
  • Table 228. Blood Coagulants Recombinant Coagulation Factor , by Region USD Million (2025-2030)
  • Table 229. Blood Coagulants Plasma-Derived Coagulation Factor , by Region USD Million (2025-2030)
  • Table 230. Blood Coagulants: by End-Users(USD Million)
  • Table 231. Blood Coagulants Hospitals , by Region USD Million (2025-2030)
  • Table 232. Blood Coagulants Specialty Clinics , by Region USD Million (2025-2030)
  • Table 233. Blood Coagulants Ambulatory Surgical Centers , by Region USD Million (2025-2030)
  • Table 234. Blood Coagulants General Pharmacies , by Region USD Million (2025-2030)
  • Table 235. Blood Coagulants Others , by Region USD Million (2025-2030)
  • Table 236. Blood Coagulants: by Clot Pathway Factors(USD Million)
  • Table 237. Blood Coagulants X Factor , by Region USD Million (2025-2030)
  • Table 238. Blood Coagulants V Factor , by Region USD Million (2025-2030)
  • Table 239. Blood Coagulants II Factor , by Region USD Million (2025-2030)
  • Table 240. Blood Coagulants I Factor , by Region USD Million (2025-2030)
  • Table 241. Blood Coagulants XIII Factor , by Region USD Million (2025-2030)
  • Table 242. Blood Coagulants: by Coagulation Tests(USD Million)
  • Table 243. Blood Coagulants Complete blood count (CBC) , by Region USD Million (2025-2030)
  • Table 244. Blood Coagulants Factor V assay , by Region USD Million (2025-2030)
  • Table 245. Blood Coagulants Fibrinogen level , by Region USD Million (2025-2030)
  • Table 246. Blood Coagulants Prothrombin time (PT or PT-INR) , by Region USD Million (2025-2030)
  • Table 247. Blood Coagulants Others , by Region USD Million (2025-2030)
  • Table 248. South America Blood Coagulants, by Country USD Million (2025-2030)
  • Table 249. South America Blood Coagulants, by Type USD Million (2025-2030)
  • Table 250. South America Blood Coagulants, by Application USD Million (2025-2030)
  • Table 251. South America Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 252. South America Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 253. South America Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 254. South America Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 255. Brazil Blood Coagulants, by Type USD Million (2025-2030)
  • Table 256. Brazil Blood Coagulants, by Application USD Million (2025-2030)
  • Table 257. Brazil Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 258. Brazil Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 259. Brazil Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 260. Brazil Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 261. Argentina Blood Coagulants, by Type USD Million (2025-2030)
  • Table 262. Argentina Blood Coagulants, by Application USD Million (2025-2030)
  • Table 263. Argentina Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 264. Argentina Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 265. Argentina Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 266. Argentina Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 267. Rest of South America Blood Coagulants, by Type USD Million (2025-2030)
  • Table 268. Rest of South America Blood Coagulants, by Application USD Million (2025-2030)
  • Table 269. Rest of South America Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 270. Rest of South America Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 271. Rest of South America Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 272. Rest of South America Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 273. Asia Pacific Blood Coagulants, by Country USD Million (2025-2030)
  • Table 274. Asia Pacific Blood Coagulants, by Type USD Million (2025-2030)
  • Table 275. Asia Pacific Blood Coagulants, by Application USD Million (2025-2030)
  • Table 276. Asia Pacific Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 277. Asia Pacific Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 278. Asia Pacific Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 279. Asia Pacific Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 280. China Blood Coagulants, by Type USD Million (2025-2030)
  • Table 281. China Blood Coagulants, by Application USD Million (2025-2030)
  • Table 282. China Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 283. China Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 284. China Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 285. China Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 286. Japan Blood Coagulants, by Type USD Million (2025-2030)
  • Table 287. Japan Blood Coagulants, by Application USD Million (2025-2030)
  • Table 288. Japan Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 289. Japan Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 290. Japan Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 291. Japan Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 292. India Blood Coagulants, by Type USD Million (2025-2030)
  • Table 293. India Blood Coagulants, by Application USD Million (2025-2030)
  • Table 294. India Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 295. India Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 296. India Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 297. India Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 298. South Korea Blood Coagulants, by Type USD Million (2025-2030)
  • Table 299. South Korea Blood Coagulants, by Application USD Million (2025-2030)
  • Table 300. South Korea Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 301. South Korea Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 302. South Korea Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 303. South Korea Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 304. New Zealand Blood Coagulants, by Type USD Million (2025-2030)
  • Table 305. New Zealand Blood Coagulants, by Application USD Million (2025-2030)
  • Table 306. New Zealand Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 307. New Zealand Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 308. New Zealand Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 309. New Zealand Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 310. Australia Blood Coagulants, by Type USD Million (2025-2030)
  • Table 311. Australia Blood Coagulants, by Application USD Million (2025-2030)
  • Table 312. Australia Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 313. Australia Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 314. Australia Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 315. Australia Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 316. Rest of Asia-Pacific Blood Coagulants, by Type USD Million (2025-2030)
  • Table 317. Rest of Asia-Pacific Blood Coagulants, by Application USD Million (2025-2030)
  • Table 318. Rest of Asia-Pacific Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 319. Rest of Asia-Pacific Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 320. Rest of Asia-Pacific Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 321. Rest of Asia-Pacific Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 322. Europe Blood Coagulants, by Country USD Million (2025-2030)
  • Table 323. Europe Blood Coagulants, by Type USD Million (2025-2030)
  • Table 324. Europe Blood Coagulants, by Application USD Million (2025-2030)
  • Table 325. Europe Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 326. Europe Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 327. Europe Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 328. Europe Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 329. Germany Blood Coagulants, by Type USD Million (2025-2030)
  • Table 330. Germany Blood Coagulants, by Application USD Million (2025-2030)
  • Table 331. Germany Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 332. Germany Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 333. Germany Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 334. Germany Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 335. France Blood Coagulants, by Type USD Million (2025-2030)
  • Table 336. France Blood Coagulants, by Application USD Million (2025-2030)
  • Table 337. France Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 338. France Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 339. France Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 340. France Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 341. Italy Blood Coagulants, by Type USD Million (2025-2030)
  • Table 342. Italy Blood Coagulants, by Application USD Million (2025-2030)
  • Table 343. Italy Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 344. Italy Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 345. Italy Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 346. Italy Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 347. United Kingdom Blood Coagulants, by Type USD Million (2025-2030)
  • Table 348. United Kingdom Blood Coagulants, by Application USD Million (2025-2030)
  • Table 349. United Kingdom Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 350. United Kingdom Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 351. United Kingdom Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 352. United Kingdom Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 353. Sweden Blood Coagulants, by Type USD Million (2025-2030)
  • Table 354. Sweden Blood Coagulants, by Application USD Million (2025-2030)
  • Table 355. Sweden Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 356. Sweden Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 357. Sweden Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 358. Sweden Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 359. Finland Blood Coagulants, by Type USD Million (2025-2030)
  • Table 360. Finland Blood Coagulants, by Application USD Million (2025-2030)
  • Table 361. Finland Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 362. Finland Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 363. Finland Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 364. Finland Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 365. Ireland Blood Coagulants, by Type USD Million (2025-2030)
  • Table 366. Ireland Blood Coagulants, by Application USD Million (2025-2030)
  • Table 367. Ireland Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 368. Ireland Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 369. Ireland Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 370. Ireland Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 371. Rest of Europe Blood Coagulants, by Type USD Million (2025-2030)
  • Table 372. Rest of Europe Blood Coagulants, by Application USD Million (2025-2030)
  • Table 373. Rest of Europe Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 374. Rest of Europe Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 375. Rest of Europe Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 376. Rest of Europe Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 377. MEA Blood Coagulants, by Country USD Million (2025-2030)
  • Table 378. MEA Blood Coagulants, by Type USD Million (2025-2030)
  • Table 379. MEA Blood Coagulants, by Application USD Million (2025-2030)
  • Table 380. MEA Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 381. MEA Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 382. MEA Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 383. MEA Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 384. Middle East Blood Coagulants, by Type USD Million (2025-2030)
  • Table 385. Middle East Blood Coagulants, by Application USD Million (2025-2030)
  • Table 386. Middle East Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 387. Middle East Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 388. Middle East Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 389. Middle East Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 390. Africa Blood Coagulants, by Type USD Million (2025-2030)
  • Table 391. Africa Blood Coagulants, by Application USD Million (2025-2030)
  • Table 392. Africa Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 393. Africa Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 394. Africa Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 395. Africa Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 396. North America Blood Coagulants, by Country USD Million (2025-2030)
  • Table 397. North America Blood Coagulants, by Type USD Million (2025-2030)
  • Table 398. North America Blood Coagulants, by Application USD Million (2025-2030)
  • Table 399. North America Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 400. North America Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 401. North America Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 402. North America Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 403. United States Blood Coagulants, by Type USD Million (2025-2030)
  • Table 404. United States Blood Coagulants, by Application USD Million (2025-2030)
  • Table 405. United States Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 406. United States Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 407. United States Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 408. United States Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 409. Canada Blood Coagulants, by Type USD Million (2025-2030)
  • Table 410. Canada Blood Coagulants, by Application USD Million (2025-2030)
  • Table 411. Canada Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 412. Canada Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 413. Canada Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 414. Canada Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 415. Mexico Blood Coagulants, by Type USD Million (2025-2030)
  • Table 416. Mexico Blood Coagulants, by Application USD Million (2025-2030)
  • Table 417. Mexico Blood Coagulants, by Coagulation Factor USD Million (2025-2030)
  • Table 418. Mexico Blood Coagulants, by End-Users USD Million (2025-2030)
  • Table 419. Mexico Blood Coagulants, by Clot Pathway Factors USD Million (2025-2030)
  • Table 420. Mexico Blood Coagulants, by Coagulation Tests USD Million (2025-2030)
  • Table 421. Blood Coagulants: by Type(USD/Units)
  • Table 422. Research Programs/Design for This Report
  • Table 423. Key Data Information from Secondary Sources
  • Table 424. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Blood Coagulants: by Type USD Million (2018-2023)
  • Figure 5. Global Blood Coagulants: by Application USD Million (2018-2023)
  • Figure 6. Global Blood Coagulants: by Coagulation Factor USD Million (2018-2023)
  • Figure 7. Global Blood Coagulants: by End-Users USD Million (2018-2023)
  • Figure 8. Global Blood Coagulants: by Clot Pathway Factors USD Million (2018-2023)
  • Figure 9. Global Blood Coagulants: by Coagulation Tests USD Million (2018-2023)
  • Figure 10. South America Blood Coagulants Share (%), by Country
  • Figure 11. Asia Pacific Blood Coagulants Share (%), by Country
  • Figure 12. Europe Blood Coagulants Share (%), by Country
  • Figure 13. MEA Blood Coagulants Share (%), by Country
  • Figure 14. North America Blood Coagulants Share (%), by Country
  • Figure 15. Global Blood Coagulants: by Type USD/Units (2018-2023)
  • Figure 16. Global Blood Coagulants share by Players 2023 (%)
  • Figure 17. Global Blood Coagulants share by Players (Top 3) 2023(%)
  • Figure 18. Global Blood Coagulants share by Players (Top 5) 2023(%)
  • Figure 19. BCG Matrix for key Companies
  • Figure 20. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 21. Sanofi (France) Revenue: by Geography 2023
  • Figure 22. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 23. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 24. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 26. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 28. Novo Nordisk AS (Denmark) Revenue, Net Income and Gross profit
  • Figure 29. Novo Nordisk AS (Denmark) Revenue: by Geography 2023
  • Figure 30. Octapharma (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Octapharma (Switzerland) Revenue: by Geography 2023
  • Figure 32. SOBI (Sweden) Revenue, Net Income and Gross profit
  • Figure 33. SOBI (Sweden) Revenue: by Geography 2023
  • Figure 34. Shire (Republic of Ireland) Revenue, Net Income and Gross profit
  • Figure 35. Shire (Republic of Ireland) Revenue: by Geography 2023
  • Figure 36. CSL Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 37. CSL Limited (Australia) Revenue: by Geography 2023
  • Figure 38. Global Blood Coagulants: by Type USD Million (2025-2030)
  • Figure 39. Global Blood Coagulants: by Application USD Million (2025-2030)
  • Figure 40. Global Blood Coagulants: by Coagulation Factor USD Million (2025-2030)
  • Figure 41. Global Blood Coagulants: by End-Users USD Million (2025-2030)
  • Figure 42. Global Blood Coagulants: by Clot Pathway Factors USD Million (2025-2030)
  • Figure 43. Global Blood Coagulants: by Coagulation Tests USD Million (2025-2030)
  • Figure 44. South America Blood Coagulants Share (%), by Country
  • Figure 45. Asia Pacific Blood Coagulants Share (%), by Country
  • Figure 46. Europe Blood Coagulants Share (%), by Country
  • Figure 47. MEA Blood Coagulants Share (%), by Country
  • Figure 48. North America Blood Coagulants Share (%), by Country
  • Figure 49. Global Blood Coagulants: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Sanofi (France)
  • Abbott Laboratories (United States)
  • Bayer AG (Germany)
  • Pfizer Inc. (United States)
  • Novo Nordisk AS (Denmark)
  • Octapharma (Switzerland)
  • SOBI (Sweden)
  • Shire (Republic of Ireland)
  • CSL Limited (Australia)
Additional players considered in the study are as follows:
BPL (United Kingdom) , Kedrion (Italy)
Select User Access Type

Key Highlights of Report


Jan 2024 205 Pages 56 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Blood Coagulants Market Quantitative research analysis
Global Blood Coagulants Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Sanofi (France), Abbott Laboratories (United States), Bayer AG (Germany), Pfizer Inc. (United States), Novo Nordisk AS (Denmark), Octapharma (Switzerland), SOBI (Sweden), Shire (Republic of Ireland) and CSL Limited (Australia) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rise in Technology at Plasma Collection Centers to Collect Plasma and Record Patient History" is seen as one of major influencing trends for Blood Coagulants Market during projected period 2023-2030.
The Blood Coagulants market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Blood Coagulants Market Report?

Have a Query? Click Here

Other Related Reports

Dural Repair Comprehensive Study by Type (Sheets, Patches, Plugs, Glues, Others), Application (Neurosurgery, Spine Surgery, Maxillofacial Surgery, Others), End Users (Hospitals, Clinics, Research Ins...
$ 3500
Dysautonomia Comprehensive Study by Type (Neurocardiogenic Syncope, Postural Orthostatic Tachycardia Syndrome, Multiple System Atrophy, Autonomic Dysreflexia, Baroreflex Failure, Others), Treatment (...
$ 3750
Coronavirus Comprehensive Study by Type (Middle East Respiratory Syndrome (MERS) {MER-CoV}, Severe Acute Respiratory Syndrome (SARS) {SAR-CoV}), Application (Hospitals, Research Laboratories, Clinics...
$ 3650
Hunter Syndrome Treatment Comprehensive Study by Type (Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplant (HSCT), Others), End-user (Life Science Companies, Research Institutes, Hos...
$ 3500
Acute Wound Care Comprehensive Study by Type (Infection Management, Exudate Management,, Active Wound Care, Therapy Devices), Wounds (Surgical Wounds, Traumatic Wounds), End-user (Long- Term Care Fac...
$ 3450
Vascular Injury Treatment Comprehensive Study by Type (Lateral Arteriorrhaphy/Venorrhaphy, Patch Angioplasty, Bypass Graft, Extraanatomic Bypass, Thrombectomy, Others), Application (Hospitals, Clinic...
$ 3650